Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab

Cancer Biology and Therapy

Volumn 13, Issue 2, 2012, Pages 114-122

  Barboza, Nora M ^a   Medina, Daniel J ^a   Budak Alpdogan, Tulin ^a   Aracil, Miguel ^b   Jimeno, José M ^c   Bertino, Joseph R ^a   Banerjee, Debabrata ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b PHARMAMAR S A   (Spain)

^c Pangaea Biotech   (Spain)

Author keywords

Combination therapy; Lymphoma; Plitidepsin; Rituximab; Synergy

Indexed keywords

CASPASE 3; CASPASE 7; CD20 ANTIGEN; DEHYDRODIDEMNIN B; DOXORUBICIN; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; FEMALE; IC 50; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOMA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL TIME; TUMOR ENGRAFTMENT; WESTERN BLOTTING;

EID: 84856752960     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.2.18876     Document Type: Article

References (42)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951
2. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69; PMID:15210744; http://dx.doi.org/10.1084/jem. 20040119
3. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006; 203: 743-53; PMID:16520392; http://dx.doi.org/10.1084/jem.20052283
4. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006; 29:388-97; PMID:16799334; http://dx.doi.org/10. 1097/01.cji.0000203081.43235.d7
5. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent lowgrade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001; PMID:9818074; http://dx.doi.org/10.1023/A:1008416911099
6. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23; PMID:15494430; http://dx.doi.org/10.1182/blood-2004-08-3175
7. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, et al. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2005; 23:1500-6; PMID:15632411; http://dx.doi.org/10.1200/JCO.2005.05.004
8. Economopoulos T, Fountzilas G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodouloe C, et al. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J 2003; 4:110-5; PMID:12750729; http://dx.doi.org/10.1038/sj.thj.6200229
9. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 2005; 10:150-9; PMID:15709217; http://dx.doi.org/10.1634/theoncologist.10-2-150
10. Jonathan W, Friedberg JW. Unique Toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2005; 1:329-34.
11. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-43; PMID:10963642
12. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-76; PMID:10458242
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-42; PMID:11807147; http://dx.doi.org/10.1056/NEJMoa011795
14. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdalla R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23:4117-26; PMID:15867204; http://dx.doi.org/10.1200/JCO.2005.09.131
15. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive Non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46:1569-73; PMID:16236611; http://dx.doi. org/10.1080/10428190500217312
16. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803-43; PMID:12662126; http://dx.doi.org/10.2165/00003495-200363080-00005
17. Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, et al. Phase II randomized study of plitidepsin (Aplidin), alone or in association with Lcarnitine, in patients with unresectable advanced renal cell carcinoma. Marine Drugs 2009; 7:57-70; PMID: 19370171; http://dx.doi.org/10. 3390/md7010057
18. Mateos MV, Cibeira T, Richardson PG, Prosper F, Oriol A, de la Rubia J, et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hours infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 2010; 16:3260-9; PMID:20530693; http://dx.doi. org/10.1158/1078-0432.CCR-10-0469
19. Urdiales JL, Morata P, DeCastro IN, Sánches-Jiménez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102:31-7; PMID: 8603376; http://dx.doi.org/10.1016/0304-3835(96)04151-1
20. (R) in the 5TMM syngeneic models of multiple myeloma. Br J Cancer 2008; 98:1966-74; PMID:18521088; http://dx.doi.org/10.1038/sj.bjc.6604388
21. Faivre S, Chièze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro E, et al. Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide, in Patients With Advanced Malignancies. J Clin Oncol 2005; 23:7780-2; PMID:16204006; http://dx.doi.org/10.1200/JCO.2005.09.357
22. Maroun JA, Belanger K, Seymour L, Matthews S, Roach J, Dionne J, et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 2006; 17:1371-8; PMID:16966366; http://dx.doi.org/10.1093/annonc/mdl165
23. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by plitidepsine. Br J Cancer 2002; 86:1510-7; PMID:11986788; http://dx.doi.org/10. 1038/sj.bjc.6600265
24. Erba E, Serafini M, Gaipa G, Tognon G, Marchini S, Celli N, et al. Effect of Plitidepsin in acute lymphoblastic leukaemia cells. Br J Cancer 2003; 89:763- 73; PMID:12915891; http://dx.doi.org/10.1038/sj.bjc.6601130
25. González-Santiago L, Suarez Y, Zarich N, Muñoz- Alonso MJ, Cuadrado A, Martínez T, et al. Plitidepsin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 2006; 13:1968-81; PMID:16543941; http://dx.doi.org/10.1038/sj.cdd. 4401898
26. Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GS, Elisseyeff Y, et al. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Leukemia 2007; 21:2399-405; PMID:17713546; http://dx.doi.org/10.1038/sj.leu.2404911
27. Ferme C, Mateos MV, Szyldergemajn S, Zucca E, Extremera S, Briones J, et al. Aplidin (Plitidepsin) Activity in Peripheral T-cell Lymphoma (PTCL): Final results. Abstract 1767. 2010 ASH Annual meeting Abstracts, volume 116, number 21. Nov 19, 2010.
28. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
29. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt- Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204:55-63; PMID:11006018; http://dx.doi.org/10.1006/cimm.2000.1693
30. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8; PMID:10845926
31. Mathas S, Rickers A, Bommert K. Do:rken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60:7170-6; PMID:11156427
32. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107:176-82; PMID:12383196; http://dx.doi.org/10. 1046/j.1365-2567.2002.01495.x
33. Cuadrado A, González L, Suárez Y, Teresa Martínez T, Muñoz A. JNK activation is critical for AplidinTMinduced apoptosis. Oncogene 2004; 23:4673-80; PMID:15122339; http://dx.doi.org/10.1038/sj.onc. 1207636
34. García-Fernández LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, Gonzáles L, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002; 21:7533-44; PMID: 12386816; http://dx.doi.org/10.1038/sj.onc.1205972
35. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial- mediated mechanism. Clin Cancer Res 2003; 9:1535-45; PMID: 12684430
36. Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, et al. Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti- CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000; 96:282-7; PMID:10891463
37. Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother 2007; 56:1107-17; PMID:17160682; http://dx.doi.org/10.1007/s00262- 006-0260-5
38. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti- CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 2008; 112:830-5; PMID:18502830; http:// dx.doi.org/10.1182/ blood-2008-01-132142
39. Gómez SG, Bueren JA, Faircloth GT, Jimeno J, Albella B. In vitro toxicity of three new antitumoral drugs (trabectedin, Aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 2003; 31:1104-11; PMID:14585376
40. Maier A, Korrat A, Fiebig H, Doreen L, Guillén MJ, Cuevas C, et al. Evaluation of antitumor efficacy of Plitidepsin in vitro in 72 patient derived tumor xenografts using a clonogenic assay and determination of a predictive gene signature. AACR-NCI-EORTC. 2007.
41. Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008; 68:5216-25; PMID:18593922; http://dx.doi.org/10.1158/0008-5472.CAN-07-5725
42. Faivre S, Chièze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, et al. Phase I and pharmacokinetic study of Aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005; 23:7871-80; PMID:16172454; http://dx.doi.org/10.1200/JCO.2005.09.357